Comparative Study of Dezocine and Ketorolac Tromethamine in Patient-Controlled Intravenous Analgesia of Laparoscopic Cholecystectomy

Yidan Ying¹, Shuke Fei², Zhiying Zeng³, Xiaoyong Qu² and Zemin Cao¹*

¹ Department of Pharmacy, Hengyang Medical School, The Second Affiliated Hospital of South China, University of South China, Hengyang, China, ² Department of Hepatobiliary and Pancreatic Surgery, Hengyang Medical School, The Second Affiliated Hospital of South China, University of South China, Hengyang, China, ³ Department of Anesthesiology, Hengyang Medical School, The Second Affiliated Hospital of South China, University of South China, Hengyang, China

Purpose: This study aimed to observe the application value of dezocine and ketorolac tromethamine in patient-controlled intravenous analgesia (PCIA) of patients undergoing laparoscopic cholecystectomy (LC).

Methods: A total of 154 patients who underwent LC surgery in our hospital and received PCIA after surgery from September 2020 to September 2021 were selected, they were divided into group A (n = 77) and group B (n = 77). Group A was given dezocine and group B was given ketorolac tromethamine. The analgesia, sedation, comfort, and adverse reactions of the two groups were closely observed at 4, 8, 12, and 24 h after surgery.

Results: At 4, 8, 12, and 24 h after surgery, the visual analog scale scores in group B were lower than those in group A (P < 0.05). At 4, 8, 12, and 24 h after surgery, the Ramsay scores in group B were higher than those in group A (P < 0.05). At 4, 8, 12, and 24 h after surgery, there was no significant difference in Bruggmann comfort scale scores between the two groups (P > 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).

Conclusion: Both dezocine and ketorolac tromethamine have high clinical application value in patients who underwent LC surgery and received PCIA, with higher patient comfort and fewer adverse reactions. But compared with dezocine, ketorolac tromethamine can achieve better sedative and analgesic effects, which is worthy of clinical promotion.

Keywords: laparoscopic cholecystectomy, dezocine, ketorolac tromethamine, patient-controlled intravenous analgesia, sedation
INTRODUCTION

Laparoscopic cholecystectomy (LC) has the advantages of short surgery time, good surgical vision, less trauma, less blood loss, easy recovery, and low infection rate, among others. It has been favored and accepted by clinicians and patients and has become the routine surgery of cholecystectomy (1). However, after LC, surgical trauma and pneumoperitoneum will lead to different degrees of physiological pain and discomfort in patients after surgery. This will cause a series of strong stress reactions in the body and may lead to fear, anxiety, irritability, and other adverse emotions, as well as respiratory, circulatory, endocrine, and other dysfunction of the body. These circumstances thus increase the disease burden of patients, slow down the recovery speed after surgery, and lower the quality of life (2, 3). According to the research report, the incidence of postoperative incision pain in patients who underwent LC is as high as 79.2%, and it mainly occurs within 24 h after surgery, which is not conducive to the physical and mental health of patients (4). Therefore, the analgesia and sedation for patients after LC has become an important link for patients to get through the postoperative pain period smoothly.

Relieving postoperative pain of patients undergoing LC is one of the important tasks for clinicians. At present, patient-controlled intravenous analgesia (PCIA) after LC has been widely used in clinics. PCIA refers to when patients feel pain, they can adjust the timing and dosage of intravenous injection of painkillers according to their needs, so as to meet the patient’s analgesic needs (5). This method is easy to operate, has an obvious analgesic effect, and embodies the consciousness of patients’ active participation in analgesia. Moreover, the injection dose of painkillers is within the range set by doctors, and it is safe (6). PCIA can relieve patients’ pain, promote early recovery of patients, and reduce economic burden and medical disputes (7).

In recent years, a variety of analgesic drugs have been continuously and widely developed in the PCIA field. Dezocine and tromethamine ketorolac are both favored for PCIA in clinics. Both of them have certain analgesic effects, but there is limited clinical research on the difference of analgesic effects between these two analgesic methods. In this study, 154 patients who underwent LC surgery and were given PCIA after surgery were selected as the research object. We investigated the analgesic and sedative effects, comfort, and safety of dezocine and tromethamine ketorolac for PCIA.

MATERIALS AND METHODS

Research Object

In this study, 154 patients who underwent LC surgery in our hospital and received PCIA after surgery from September 2020 to September 2021 were selected, they were divided into group A (n = 77) and group B (n = 77). (1) Inclusion criteria were: compliance with surgical indications; normal mental and cognitive function; and complete case data. (2) Exclusion criteria were: already received second surgery; used drugs within 24 h of surgery that could affect the efficacy of the study drug; important organ dysfunction; drug dependent and/or drug addict; with severe immune system diseases; with severe hypertension and diabetes; and allergic to research drugs.

Research Methods

Patients in both groups were not given analgesia treatment before surgery. Patients were treated with LC, and the venous channel was established. Induction of anesthesia in the patient was carried out using midazolam 1.5 mg/kg, sufentanil 0.3 µg/kg, and rocuronium 0.6 mg/kg. Then, tracheal intubation anesthesia was administered using sevoflurane, sufentanil 0.15–0.3 µg/kg, and propofol 4 with a concentration of 1–2% during surgery. In the process of using PCIA, patients and their families should be informed of the correct use of analgesic pumps, including how to make analgesic score, how to give medicine by pressing, common side effects, and so on. After surgery, the two groups were connected with the patient-controlled analgesia pump, and all patients were given sufentanil 2 µg/kg. On this basis, group A was given dezocine 0.3 mg/kg, diluted with 100 ml normal saline, and intravenously pumped. Group B was given ketorolac tromethamine 2 mg/kg, diluted with 100 ml normal saline, and intravenously pumped. The infusion rate of the two groups was 2 ml/h, the single self-controlled pressing dose was 2 ml, and the locking time was 15 min. The duration of analgesia was individualized according to the patient’s needs.

Observation Index

The analgesia, sedation, comfort, and adverse reactions of the two groups were closely observed at 4, 8, 12, and 24 h after surgery, and detailed records were made. (1) Analgesia: the visual analog scale (VAS) score was used. In brief, we took a 10 cm scale ruler and asked the patient to mark a scale that can represent their pain degree on the top using a scale of 10 points, with 0 point being painless and 10 points being severe pain. VAS score was assessed by medical staff who were unaware of the patient’s condition. (2) Sedation: the Ramsay score was used with the following indicators: 1 point: Sober but anxious; 2 points: Quiet cooperation; 3 points: Sleepy but awake; 4 points: Shallow sleep could wake up; 5 points: Deep sleep but slow response; and 6 points: Deep sleep, no response to call. (3) Comfort: the Bruggmann comfort scale (BCS) was used with the following scores: 0 point: Persistent pain; 1 point: Painless when quiet, heavy pain when breathing deeply or coughing; 2 points: Painless when quiet, slightly painful when breathing deeply or coughing; 3 points: Painless breathing; 4 points: Cough or other actions are painless; and 5–6 points: Excessive sedation. (4) Adverse reactions were recorded whether there were any adverse reactions such as nausea, vomiting, dizziness, dry mouth, skin pruritus, and urinary retention within 3 days after surgery in both groups.

Statistical Methods

For statistical analysis, SPSS 22 (Armonk, NY: IBM Corp.) was used for data processing. The measurement data conforming to the normal distribution were expressed as mean ± SD. Paired sample t-test was used for intra-group comparison, while an independent-sample t-test was used for inter-group comparison. The counting data were expressed by %, and the χ² test was used for comparison. P < 0.05, the difference was statistically significant.
TABLE 1 | Comparison of two groups of general information.

| Group   | Case number | Gender | Age (years) | Intraoperative blood loss (ml) | Surgery time (min) |
|---------|-------------|--------|-------------|-------------------------------|-------------------|
|         |             | Male   | Female      |                               |                   |
| Group A | 77          | 42 (54.55%) | 35 (45.45%) | 45.92 ± 9.36                  | 8.73 ± 1.24       |
| Group B | 77          | 39 (50.65%) | 38 (49.35%) | 46.27 ± 9.50                  | 8.56 ± 1.19       |

χ²/t value

0.234 0.230 0.867 1.564

P value

0.628 0.818 0.386 0.119

RESULTS

General Information
There was no significant difference in gender, age, intraoperative blood loss, and surgery time between the two groups (P > 0.05; Table 1).

Analgesic Situation
At 4, 8, 12, and 24 h after surgery, the VAS scores in group B were lower than those in group A (P < 0.05; Figure 1).

Sedation Situation
At 4, 8, 12, and 24 h after surgery, the Ramsay scores in group B were higher than those in group A (P < 0.05; Figure 2).

Comfort Situation
At 4, 8, 12, and 24 h after surgery, there was no significant difference in BCS scores between the two groups (P > 0.05; Figure 3).

Adverse Reactions
There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05; Table 2).

DISCUSSION

Laparoscopic cholecystectomy surgery has a significant positive effect as an effective method for the clinical treatment of cholecystitis, cholecystolithiasis, and other gallbladder diseases (8). However, due to factors such as diaphragm traction and visceral mucosa hypoxia after CO₂ pneumoperitoneum, patients after LC are prone to pain symptoms, which affects their physical and mental health and prognosis recovery (9). Postoperative pain can inhibit the patient's breathing activity, increase the patient's blood pressure, increase the oxygen consumption of myocardium, inhibit gastrointestinal peristalsis, reduce the body's resistance, and easily cause some negative emotions, thus affecting the prognosis of the disease (10, 11). Therefore, how to effectively relieve postoperative pain of patients is of great significance to the physical and mental health of patients. At
Dezocine is a potent opioid analgesic with both exciting and antagonistic effects (12). On the one hand, dezocine mainly achieves analgesic and sedative effects by exciting K receptors distributed in the brain, spinal cord, and brain stem (13). On the other hand, dezocine is also a µ-receptor antagonist, which has no typical µ-receptor dependence, so it can relax gastrointestinal smooth muscle with fewer adverse reactions (14). At the same time, dezocine can inhibit the activities of endothelin and renin in the body, reduce the release of angiotensin II and inflammatory factors, thereby reducing the excessive stress reaction of patients after LC (15). Dezocine has similar effects to morphine in onset time, action time, and intensity of action, and it is not easy to produce tolerance and can maintain the relative stability of blood volume and hemodynamics (16).

Ketorolac tromethamine is a non-steroidal anti-inflammatory drug with the best analgesic effect at present, and its analgesic effect is 7.5 times that of morphine, which is suitable for short-term treatment of acute moderate, and severe pain (17). It has strong analgesic and sedative effects in many aspects, and the specific mechanisms are as follows: ① Prostaglandin is an important mediator that causes inflammation such as redness, swelling, heat, and pain in the body. Ketorolac tromethamine can reduce the synthesis of prostaglandins by inhibiting the activity of peripheral and central cyclooxygenase, thereby reducing the degree of inflammatory reaction in tissues and relieving the stimulation of inflammatory medium to nerve endings, so as to achieve the analgesic effect (18). ② The medicine can reduce the response of pain nerves to endogenous inflammatory factors, and passivate peripheral nerves in advance to prevent peripheral nerve sensitization, thereby reducing the body's response to stressors, inhibiting sympathetic nerve excitation and thus reducing the level of stress factors, reducing the pain of patients after LC (19). ③ This medicine is not only beneficial to alleviate the wound inflammatory reaction and tissue edema caused by LC, but also affects the synthesis and activity of other nerve active substances and prevents the nerve active substances of nociceptive stimulation from being conducted to the spinal nerve (20). ④ Ketorolac tromethamine can selectively aggregate the pain site, thus increasing the drug concentration, which makes the analgesic effect stronger, the action time longer, and the sedative effect stronger (21). ⑤ Some scholars have found that ketorolac tromethamine may have an effect on the hypothalamic prostate system In addition, its analgesic effect may be related to the synthesis and participation of nitric oxide (22, 23). However, more experiments are needed to confirm this conclusion.

The commonly used multimodal analgesia in clinical practice is sufentanil combined with dezocine. Sufentanil has a longer sedative effect time and less inhibitory effect on respiratory function. Sufentanil has strong lipophilicity and a higher rate of passing through the blood-brain barrier, thereby increasing the binding rate to plasma proteins, subsequently achieving an analgesic effect. The results showed that within 24 h after surgery, the VAS score of group B was lower, the Ramsay score of this group was higher, and there was no significant difference in BCS score and incidence of adverse reactions between group A and group B. We believe that both dezocine and ketorolac tromethamine have high clinical application value in patients who underwent LC surgery and received PCIA, with higher patient comfort and less adverse reactions. But compared with dezocine, ketorolac tromethamine can achieve better sedative and analgesic effects. At present, the common clinical adverse reactions are nausea and vomiting, and serotonin receptor blockers and glucocorticoids are the first-line drugs to deal with nausea and vomiting. If both are ineffective, droperidol can be used. In addition, other possible adverse reactions include dizziness, dry mouth, skin pruritus, and urinary retention, which

![Figure 3](image_url)  
**FIGURE 3** | Comparison of comfort between two groups.

| Group   | Case number | Nausea   | Vomiting  | Dizziness | Dry mouth | Skin pruritus | Urinary retention | Total |
|---------|-------------|----------|-----------|-----------|-----------|--------------|-------------------|-------|
| Group A | 77          | 4 (5.19%)| 2 (2.59%) | 1 (1.30%) | 1 (1.30%) | 1 (1.30%)    | 0 (0.00%)         | 9 (11.69%) |
| Group B | 77          | 2 (2.59%)| 2 (2.59%) | 1 (1.30%) | 0 (0.00%) | 0 (0.00%)    | 0 (0.00%)         | 5 (6.49%) |

χ² value: 1.257
P value: 0.262
generally do not require special treatment. It is worth mentioning that there are still some shortcomings in this study, such as the following: the scheme is a single-center study, and hence multicenter research needs to be carried out in the follow-up study. The infusion rates of both groups were 2 ml/h, and only one PCIA infusion rate was used. The PCIA infusion rate should be adjusted individually according to the needs of patients. The doses of dezocine and ketorolac tromethamine have not been classified hierarchically, and we still need to improve the research (24–26).

CONCLUSION

Both dezocine and ketorolac tromethamine have high clinical application value in patients who underwent LC surgery and received PCIA, with higher patient comfort and fewer adverse reactions. However, compared with dezocine, ketorolac tromethamine can achieve better sedative and analgesic effects, which is worthy of clinical promotion.

REFERENCES

1. Barazanchi AWH, MacFater WS, Rahiri JL, Tutone S, Hill AG, Joshi GP, et al. Evidence-based management of pain after laparoscopic cholecystectomy: a PROSPECT review update. Br J Anaesth. (2018) 121:787–803. doi: 10.1016/j.bja.2018.06.023
2. Efekharharyadi M, Ansari M, Darvishi-Khezri H, Zardosh R. Pharmacological methods of postoperative pain management after laparoscopic cholecystectomy: a review of meta-analyses. Surg Laparosc Endosc Percutan Tech. (2020) 30:534–41. doi: 10.1097/SLE.0000000000000824
3. Wei X, Yao X. The impact of intraperitoneal levobupivacaine on pain relief after laparoscopic cholecystectomy: a meta-analysis of randomized controlled studies. Surg Laparosc Endosc Percutan Tech. (2020) 30:1–6. doi: 10.1097/SLE.0000000000000742
4. Mitra S, Khandelwal P, Roberts K, Kumar S, Vadivelu N. Pain relief in laparoscopic cholecystectomy—a review of the current options. Pain Pract. (2012) 12:485–96. doi: 10.1111/j.1533-2500.2011.00513.x
5. Zheng J, Han W, Han XD, Ma XY, Zhang P. Effect of naloxone on intravenous fentanyl patient-controlled analgesia after laparoscopic cholecystectomy. Medicine (Baltimore). (2016) 95:e5074. doi: 10.1097/MD.0000000000005074
6. Jung KT, So KY, Kim SC, Kim SH. Effect of nefopam-based patient-controlled analgesia with and without fentanyl on postoperative pain intensity in patients following laparoscopic cholecystectomy: a prospective, randomized, controlled, double-blind non-inferiority trial. Medicina (Kaunas). (2021) 57:316. doi: 10.3390/medicina57040316
7. Onaka H, Ishikawa M, Mizuguchi Y, Uchida E, Sakamoto A. Evaluation of postoperative pain control and quality of recovery in patients using intravenous patient-controlled analgesia with fentanyl: a prospective randomized study. J Nippon Med Sch. (2016) 83:158–66. doi: 10.1272/jnms.83.158
8. Jesus RR, Leite AM, Leite SS, Vieira MC, Villela NR. Anesthetic therapy for acute pain relief after laparoscopic cholecystectomy: systematic review. Rev Col Bras Cir. (2018) 45:e1885. doi: 10.1590/0100-6991e-20181885
9. Gin E, Lowen D, Tacey M, Hodgson R. Reduced laparoscopic intra-abdominal pressure during laparoscopic cholecystectomy and its effect on post-operative pain: a double-blinded randomised control trial. J Gastrointest Surg (2021) 25:2806–13. doi: 10.1007/s11665-021-04919-0
10. Zhu J, Xie H, Zhang L, Chang L, Chen P. Efficiency and safety of ketamine for pain relief after laparoscopic cholecystectomy: A meta-analysis from randomized controlled trials. Int J Surg. (2018) 49:1–9. doi: 10.1016/j.ijsu.2017.11.031
11. Arraiza N, Papuzinski C, Kirmayr M, Matta M, Aranda F, Stojanova J, et al. Efficacy of methadone for the management of postoperative pain in laparoscopic cholecystectomy: A randomized clinical trial. Medwave. (2021) 21:e18315. doi: 10.5867/medwave.2021.02.8134
12. Zhao P, Wu Z, Li C, Yang G, Ding J, Wang K, et al. Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: a randomized, controlled, double-blind trial. PLoS ONE. (2020) 15:e0233412. doi: 10.1371/journal.pone.0233412
13. Dong Y, Liang Z, Xu Z, Hao W, Wang D, Huo S, et al. Effects of dezocine, morphine and nalbuphine on electropain threshold, temperature pain threshold and cardiac function in rats with myocardial ischemia. Ann Palliat Med. (2020) 9:1556–63. doi: 10.21037/apm-19-460
14. Zhu H, Chen Y, Huang S, Sun X. Interaction of analgesic effects of dezocine and sufentanil for relief of postoperative pain: a pilot study. Drug Des Devel Ther. (2020) 14:4717–24. doi: 10.2147/DDDT.S270478
15. Zhou L, Zhang Y, Sun H, Hu R, Wang J, Xu G. Effect of preemptive dezocine before general anesthesia on postoperative analgesia in patients undergoing laparoscopic cholecystectomy: a prospective observational study. Medicine (Baltimore). (2018) 97:e12533. doi: 10.1097/MD.0000000000012533
16. Wang L, Liu X, Wang J, Sun Y, Zhang G, Liang L. Comparison of the efficacy and safety between dezocine injection and morphine injection for persistent pain in Chinese cancer patients: a meta-analysis. Biosci Rep. (2017) 37: BSR20170243. doi: 10.1042/BSR20170243
17. Tian Z, Hu B, Miao M, Zhang L, Wang L, Chen B. Ketorolac tromethamine pretreatment suppresses sufentanil-induced cough during general anesthesia induction: a prospective randomized controlled trial. BMC Anesthesiol. (2020) 20:205. doi: 10.1186/s12871-020-01124-5
18. Burdick M, Mamelo R, Hurliman M, Dupuis M, Xie Y, Grenier J, et al. Comparison of the pharmacokinetics of ketorolac tromethamine after continuous subcutaneous infusion and repeat intramuscular bolus injections in healthy adult subjects. Clin Pharmacol Drug Dev. (2017) 6:343–9. doi: 10.1002/cpdd.319
19. Zhang Y, Sun X, Liang J, Wang X, Cao X. Observation of analgesic effect of dezocine injected into wounds in healthy adult subjects. Panminerva Med. (2021) 62:289–95. doi: 10.2337/S0031-0088.19.03662-0
20. Wagner-Kovacec J, Povalej-Brzan P, Mekis D. Efficacy of continuous infusion of levobupivacaine and ketorolac for post-caesarean section analgesia: a prospective, randomised, double-blind, placebo-controlled trial. BMC Anesthesiol. (2018) 18:165. doi: 10.1186/s12871-018-0609-2

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of South China. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YY is the mainly responsible for the writing of the article. SF is mainly responsible for research design. ZZ and XQ are mainly responsible for data analysis. ZC is responsible for the guidance of the entire research. All authors contributed to the article and approved the submitted version.
21. Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. *Ann Emerg Med.* (2017) 70:177–84. doi: 10.1016/j.annemergmed.2016.10.014

22. Ghanizada H, Al-Karagholi MA, Arrngrim N, Merch-Rasmussen M, Metcalf-Clausen M, Larsson HBW, et al. Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. *J Headache Pain.* (2020) 21:19. doi: 10.1186/s10194-020-01089-3

23. Lázaro-Ibáñez GG, Torres-López JE, Granados-Soto V. Participation of the nitric oxide-cyclic GMP-ATP-sensitive K(+) channel pathway in the antinociceptive action of ketorolac. *Eur J Pharmacol.* (2001) 426:39–44. doi: 10.1016/s0014-2999(01)01206-7

24. Miyoshi H, Nakamura R, Noda Y, Yokomi H, Kamiya S, Morio A, et al. Intravenous patient-controlled analgesia does not increase the risk of postoperative delirium compared to patient-controlled epidural analgesia: a propensity score-matched retrospective cohort study. *Ann Palliat Med.* (2021) 10:10160–9. doi: 10.21037/apm-21-1084

25. Lu S, Ma SC, Wang YY, Zhu ZH, Fan HW, Zhao GQ. Comparison of pain relief between patient-controlled epidural analgesia and patient-controlled intravenous analgesia for patients undergoing spinal fusion surgeries. *Arch Orthop Trauma Surg.* (2015) 135:1247–55. doi: 10.1007/s00402-015-2263-1

26. Chen S, Xu Z, Liu H, Zhang Y, Zhang J, Chen Y, et al. Perioperative patient-controlled regional analgesia versus patient-controlled intravenous analgesia for patients with critical limb ischaemia: a study protocol for a randomised controlled trial. *BMJ Open.* (2020) 10:e037879. doi: 10.1136/bmjopen-2020-037879

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ying, Fei, Zeng, Qu and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.